News

Moderna and Carisma establish collaboration to develop in vivo engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

Details

Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that the two companies have entered into a strategic collaboration agreement to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer. 

Creative Balloons appoints David Johnson as Chairman of the Board of Directors

Details

Creative Balloons GmbH, Waghäusel near Heidelberg, a specialist in medical technology, today announced the appointment of David Johnson as Chairman of the Board of Directors, effective January 1, 2022. 

ONWARD Announces Completion of Enrollment in the Up- LIFT Pivotal Trial of ARC Therapy for Spinal Cord Injury

Details

ONWARD, today announces it has completed enrollment in the Up-LIFT study, a pivotal trial to evaluate the safety and effectiveness of ARC Therapy to restore hand and arm function in people with spinal cord injury (SCI). Up-LIFT is the first large-scale pivotal trial of non-invasive spinal cord stimulation technology. 

  1. Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
  2. Confo Therapeutics Enters Collaborative Agreement with Regeneron
  3. ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine
  4. iOmx Therapeutics raises EUR 65 million in Series B round
© Wellington Partners, 2022.